Clinical Activity and Broken Immunologic Tolerance From Ex Vivo Gm-CSF Gene Transduced Prostate Cancer Vaccines

Simons, Jonathan W.; Mikhak, Bahar; Chang, Ju Fay; DeMarzo, Angelo M.; Lim, Michael; Carducci, Michael A.; Goemann, Marti; Marshall, Fray F.; Weber, Christine E.; Piantadosi, Steven; Nelson, William G.

doi:10.1097/00005392-199904010-00206

“…However, it is noteworthy that a large number of pDNA (700-800 copies) are delivered to the nucleus, even in cells with a low expression. 398 When a lipoplex is systemically administered, high levels of IL-12 and INF-g are produced, most probably due to the inflammatory effect of the lipoplex itself, and the innate and adaptive immuneresponses appear, irrespective of the gene expression form of pDNA. For an examination of the relationship between decondensation and gene expression in living cells, imaging of fluorescence resonance energy transfer (FRET) among donors and acceptors labeled on pDNA is a useful technique.…”

Section: Heterogeneity In Transfectionmentioning

confidence: 99%

Delivery of Nucleic Acids and Gene Delivery

Akita¹,

Hatakeyama²,

Khalil³

et al. 2011

Comprehensive Biomaterials

View full text Add to dashboard Cite

“…Patients were vaccinated weekly for 8 weeks with irradiated, GM-CSF secreting PC-3 and LNCaP prostate cancer cells. One of 21 patients had a partial PSA response of less than 7 months' duration, 14 had stable disease, and 6 progressed [14]. At 3 months after treatment, PSA velocity or PSA slope decreased in 71% of patients.…”

Section: Immunotherapymentioning

confidence: 99%

Gene therapy for prostate cancer

Gingrich

¹

,

Chauhan

²

,

Steiner

³

2001

Curr Urol Rep

1

0

View full text Add to dashboard Cite

Basic research continues to unravel the molecular complexity of normal and abnormal biologic processes. The development of means to affect the expression level of genes that promote or contribute to cellular transformation, invasion, and metastasis has spawned the concept of gene therapy. This relatively new field seeks to reverse or suspend the pathologic progression of a variety of diseases including the malignant transformation of prostatic epithelial cells. Initial clinical trials for prostate cancer have thus far shown gene therapy to be relatively safe, although definitive evidence of durable therapeutic efficacy remains to be demonstrated. In this article, recent preclinical research, current therapeutic strategies, and recent results of gene therapy clinical trials for the treatment of prostate cancer are reviewed.

show abstract

“…One of 21 patients had a partial PSA response of less than 7 months' duration, 14 had stable disease, and 6 progressed [14]. Patients were vaccinated weekly for 8 weeks with irradiated, GM-CSF secreting PC-3 and LNCaP prostate cancer cells.…”

Section: Immunotherapymentioning

confidence: 99%

Gene therapy for prostate cancer

Gingrich

¹

,

Chauhan

²

,

Steiner

³

2001

View full text Add to dashboard Cite

Basic research continues to unravel the molecular complexity of normal and abnormal biologic processes. The development of means to affect the expression level of genes that promote or contribute to cellular transformation, invasion, and metastasis has spawned the concept of gene therapy. This relatively new field seeks to reverse or suspend the pathologic progression of a variety of diseases including the malignant transformation of prostatic epithelial cells. Initial clinical trials for prostate cancer have thus far shown gene therapy to be relatively safe, although definitive evidence of durable therapeutic efficacy remains to be demonstrated. In this article, recent preclinical research, current therapeutic strategies, and recent results of gene therapy clinical trials for the treatment of prostate cancer are reviewed.

show abstract

Clinical Activity and Broken Immunologic Tolerance From Ex Vivo Gm-CSF Gene Transduced Prostate Cancer Vaccines

Cited by 9 publications

References 0 publications

Delivery of Nucleic Acids and Gene Delivery

Delivery of Nucleic Acids and Gene Delivery

Gene therapy for prostate cancer

Gene therapy for prostate cancer

Contact Info

Product

Resources

About